NCI-H520Homo sapiens (Human)Cancer cell line

Also known as: NCIH520, NCI-HUT-520, H-520, H520

🤖 AI SummaryBased on 14 publications

Quick Overview

Human lung cancer cell line with known mutations and drug sensitivity profiles.

Detailed Summary

The NCI-H520 cell line is a human lung cancer cell line derived from a squamous cell carcinoma. It is widely used in cancer research for studying molecular mechanisms and drug development. This cell line has been characterized in multiple studies for its genetic mutations and response to various therapeutic agents. Research has shown that NCI-H520 exhibits specific mutations in genes such as TP53 and CDKN2A, which are commonly associated with lung cancer progression. Additionally, it has been used in studies investigating the efficacy of targeted therapies and the role of specific signaling pathways in cancer progression. The cell line's response to different drugs has been documented, making it a valuable resource for preclinical studies.

Research Applications

Molecular mechanism studiesDrug developmentGenetic mutation analysisTherapeutic efficacy testing

Key Characteristics

Mutations in TP53 and CDKN2AResponse to targeted therapiesUsed in preclinical studies
Generated on 6/17/2025

Basic Information

Database IDCVCL_1566
SpeciesHomo sapiens (Human)
Tissue SourceLung[UBERON:UBERON_0002048]

Donor Information

Age CategoryUnknown
SexMale

Disease Information

DiseaseLung squamous cell carcinoma
LineageLung
SubtypeLung Squamous Cell Carcinoma
OncoTree CodeLUSC

DepMap Information

Source TypeATCC
Source IDACH-000395_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Trp146Ter (c.438G>A)Unspecified-CelloPub=CLPUB00546
MutationSimpleCDKN2Ap.Gly45Valfs*8 (c.134delG)Homozygous-from parent cell line NCI-H520
MutationSimpleATMp.Pro383Ala (c.1147C>G)Heterozygous-from parent cell line NCI-H520

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D10S1248
13
D12S391
21
D13S317
10,11
D16S539
8,13
D18S51
17
D19S433
13,14
D1S1656
14,16.3
D21S11
30
D22S1045
16
D2S1338
18,23
D2S441
10,11
D3S1358
16
D5S818
12
D7S820
8,12
D8S1179
14,16,17
FGA
22
Penta D
13
Penta E
5,14
TH01
10
TPOX
8
vWA
18,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.

Maughan T.S., Ryan A.J.

Oncotarget 7:60807-60822(2016).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity.

Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S.

Br. J. Cancer 109:1599-1608(2013).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.

Gazdar A.F., Lam S., MacAulay C., Lam W.L.

Int. J. Cancer 118:1556-1564(2006).

Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.

Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.

Cancer Genet. Cytogenet. 125:87-99(2001).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

Mutation and expression of the DCC gene in human lung cancer.";

Yokota J.

Neoplasia 2:300-305(2000).

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Int. J. Oncol. 15:927-934(1999).

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Kohara H., Harada M.

Acta Med. Okayama 53:67-75(1999).

Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.

Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.

Br. J. Cancer 77:2162-2170(1998).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.

Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.

Cancer Res. 46:798-806(1986).

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.

Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.

J. Natl. Cancer Inst. 82:1420-1426(1990).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources